TCON - TRACON Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.9100
-0.0300 (-1.55%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close1.9400
Open1.9600
Bid1.9100 x 900
Ask1.9600 x 900
Day's Range1.8700 - 1.9697
52 Week Range0.9500 - 6.2800
Volume160,712
Avg. Volume332,090
Market Cap10.506M
Beta (5Y Monthly)2.07
PE Ratio (TTM)N/A
EPS (TTM)-5.4420
Earnings DateAug 05, 2020 - Aug 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
  • GlobeNewswire

    Proactive Virtual Event Showcases Four Rising Stars of the Life Sciences Industry

    NEW YORK, June 22, 2020 -- Proactive, the digital financial news organization, will be showcasing four rising stars of the life sciences industry with its first North American.

  • Thomson Reuters StreetEvents

    Edited Transcript of TCON earnings conference call or presentation 13-May-20 8:30pm GMT

    Q1 2020 TRACON Pharmaceuticals Inc Earnings Call

  • Should You Buy TRACON Pharmaceuticals Inc (TCON)?
    Insider Monkey

    Should You Buy TRACON Pharmaceuticals Inc (TCON)?

    In this article we will take a look at whether hedge funds think TRACON Pharmaceuticals Inc (NASDAQ:TCON) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips […]

  • GlobeNewswire

    TRACON Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

    SAN DIEGO, June 01, 2020 -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted.

  • GlobeNewswire

    TRACON Pharmaceuticals Highlights Updated Envafolimab Results in MSI-H/dMMR Colorectal Cancer and Results from Clinical Trial of Opdivo and Yervoy Combination Therapy in Undifferentiated Pleomorphic Sarcoma Conducted by Alliance for Clinical Trials in Oncology

    TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today highlighted data from poster #11511 at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, entitled,  “Multicenter phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401): Results of expansion cohorts.” Investigators from the Alliance for Clinical Trials in Oncology (Alliance), a broad community of scientists and clinicians who are committed to the prevention and treatment of cancer, reported an impressive 29% confirmed objective response rate (ORR) in patients (n=14) with highly refractory Undifferentiated Pleomorphic Sarcoma (UPS) who received Opdivo in combination with Yervoy in a non-comparative randomized trial.

  • GlobeNewswire

    TRACON Pharmaceuticals Announces Presentation of Positive Clinical Data for Envafolimab in MSI-H/dMMR Cancer at ASCO 2020 Virtual Scientific Program by its Corporate Partners 3D Medicines and Alphamab

    TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that positive data from envafolimab in a pivotal trial in China for the treatment of MSI-H/dMMR cancer will be presented by the Company’s corporate partners, 3D Medicines and Alphamab, at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program. ASCO abstract #3021 entitled “Envafolimab (KN035) in Advanced Tumors with Mismatch-Repair Deficiency” reviewed data available on December 17, 2019 from the ongoing pivotal Phase 2 trial of envafolimab given by subcutaneous injection without an adjuvant in MSI-H/dMMR cancer.

  • GlobeNewswire

    TRACON Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update

    TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced financial results for the first quarter ended March 31, 2020. In May, TRACON completed a Type B meeting with the FDA to discuss the pivotal ENVASARC trial design for the potential registration of envafolimab in multiple soft tissue sarcoma subtypes. The FDA agreed with the trial design to enroll separate noncomparative cohorts of 80 patients each with undifferentiated pleomorphic sarcoma (UPS) or myxofibrosarcoma (MFS), with the first cohort receiving single-agent envafolimab and the second cohort receiving envafolimab plus Yervoy (ipilimumab), with the primary endpoint being objective response rate by RECIST by blinded independent radiographic review in each cohort.

  • GlobeNewswire

    TRACON Pharmaceuticals Announces Successful Type B Meeting with FDA for Pivotal Study of Envafolimab in Sarcoma

    TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced the successful completion of a Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA). The FDA agreed with TRACON’s proposals regarding key elements of the pivotal ENVASARC trial for envafolimab in the soft tissue sarcoma subtypes of undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS). TRACON expects to initiate enrollment in the ENVASARC trial in the second half of 2020.

  • GlobeNewswire

    TRACON to Report First Quarter 2020 Financial Results and Company Highlights on May 13, 2020

    TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its first quarter 2020 financial and operating results after the close of U.S. financial markets on Wednesday, May 13, 2020. TRACON develops targeted therapies for cancer utilizing a capital efficient product development platform.

  • GlobeNewswire

    TRACON Pharmaceuticals Retains Global Rights to TRC253 Following Completion of a Phase 1/2 Trial

    TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, today announced that it has retained global rights to and has sole responsibility for development and commercialization of TRC253 based on Janssen Pharmaceutica N.V.’s (Janssen’s) decision not to exercise its option to reacquire global rights to TRC253 following a review of the Phase 2 data in prostate cancer patients with acquired resistance to Xtandi® or Erleada®. Under the original agreement, TRACON is obligated to make certain payments to Janssen if future development and regulatory milestones are achieved and to pay a royalty on net sales of TRC253.

  • GlobeNewswire

    TRACON Pharmaceuticals Announces Appointment of Biotechnology Industry Veteran Shahe Garabedian as Senior Vice President of Quality Assurance and Granting of Inducement Award

    TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Shahe Garabedian as Senior Vice President of Quality Assurance and the issuance of an inducement award. “We are very pleased to welcome Shahe to the TRACON senior management team,” said Dr. Charles Theuer, President and Chief Executive Officer of TRACON.

  • GlobeNewswire

    TRACON Announces May 8 Date for Type B Teleconference Meeting with FDA to Discuss Trial Design for ENVASARC: A Potential Pivotal Study of Envafolimab in Sarcoma

    TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that the U.S. Food and Drug Administration (FDA) has granted TRACON a Type B Teleconference to take place on May 8, 2020 to discuss the trial design for a potential pivotal study of envafolimab in sarcoma (ENVASARC). Enroll the first patient in ENVASARC, a potential pivotal trial of envafolimab in the U.S.

  • GlobeNewswire

    TRACON Pharmaceuticals Announces Appointment of Saundra Pelletier to Board of Directors

    TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Saundra Pelletier, Chief Executive Officer, President and Executive Director of Evofem Biosciences, Inc., to its Board of Directors. “We are very pleased to welcome Saundra to the TRACON Board,” said Dr. Charles Theuer, President and Chief Executive Officer of TRACON.

  • Thomson Reuters StreetEvents

    Edited Transcript of TCON earnings conference call or presentation 27-Feb-20 9:30pm GMT

    Q4 2019 TRACON Pharmaceuticals Inc Earnings Call

  • GlobeNewswire

    TRACON Announces Submission of Request for Type B Meeting with FDA to Discuss Trial Design for ENVASARC: A Potential Pivotal Study of Envafolimab in Sarcoma

    TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it has submitted a request for a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss the trial design for a potential pivotal study of envafolimab in sarcoma (ENVASARC). TRACON plans to propose a pivotal trial with two cohorts of approximately 80 patients each to assess the objective response rate in sarcoma subtypes known to be responsive to checkpoint inhibition, with one cohort receiving single-agent envafolimab and the second cohort receiving envafolimab and Yervoy (ipilimumab).

  • GlobeNewswire

    Santen and TRACON Discontinue Development of DE-122 for Wet Age-Related Macular Degeneration

    Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; hereinafter, “Santen”) and TRACON Pharmaceuticals, Inc. (Head Office: San Diego, CA; hereinafter, “TRACON”) today announced the discontinuation of the development of DE-122 for the treatment of wet age-related macular degeneration (wAMD) following the review of recently obtained top-line data from the Phase 2a AVANTE clinical study. The Phase 2a AVANTE clinical study is a randomized controlled trial that assessed visual acuity in wAMD patients following six monthly treatments with a combination of DE-122 and Lucentis or single agent Lucentis. Topline data indicated that DE-122 did not improve visual acuity when combined with Lucentis as compared to single agent Lucentis treatment, the primary endpoint of the trial.

  • Benzinga

    The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 27) Global Cord Blood Corp (NYSE: CO ) Cleveland BioLabs, ...

  • GlobeNewswire

    TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update

    SAN DIEGO, Feb. 27, 2020 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted.

  • GlobeNewswire

    TRACON to Report Fourth Quarter and Full Year 2019 Financial Results and Company Highlights on February 27, 2020

    SAN DIEGO, Feb. 20, 2020 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted.

  • GlobeNewswire

    TRACON Pharmaceuticals Announces Change to Nasdaq Capital Market

    SAN DIEGO, Feb. 07, 2020 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted.

  • Is TRACON Pharmaceuticals, Inc.'s (NASDAQ:TCON) CEO Pay Justified?
    Simply Wall St.

    Is TRACON Pharmaceuticals, Inc.'s (NASDAQ:TCON) CEO Pay Justified?

    Charles Theuer became the CEO of TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) in 2006. This report will, first, examine...

  • Should You Buy TRACON Pharmaceuticals Inc (NASDAQ:TCON)?
    Insider Monkey

    Should You Buy TRACON Pharmaceuticals Inc (NASDAQ:TCON)?

    With the first-quarter round of 13F filings behind us, it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was TRACON Pharmaceuticals Inc (NASDAQ:TCON). TRACON Pharmaceuticals Inc (NASDAQ:TCON) shares haven't […]

  • GlobeNewswire

    TRACON Pharmaceuticals, 3D Medicines and Jiangsu Alphamab Announce Partnership for Development of Subcutaneous PD-L1 Single-Domain Antibody in Soft Tissue Sarcoma

    Company to Host Investor Conference Call Today at 8:30 a.m. ET / 5:30 a.m. PT Envafolimab represents a potential best-in-class PD-L1 inhibitor that is injectable subcutaneously.

  • Thomson Reuters StreetEvents

    Edited Transcript of TCON earnings conference call or presentation 5-Nov-19 9:30pm GMT

    Q3 2019 TRACON Pharmaceuticals Inc Earnings Call

  • GlobeNewswire

    TRACON Pharmaceuticals Announces Reverse Stock Split

    TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer as well as wet age-related macular degeneration through a license to Santen Pharmaceutical Co. Ltd., and utilizing our product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that at the special meeting of stockholders, held November 6, 2019, stockholders voted to approve a proposal authorizing the Board of Directors of the Company to amend the Company's certificate of incorporation to effect a reverse split of TRACON’s outstanding common shares. Following the special meeting of stockholders, the Board of Directors approved a 1-for-10 reverse stock split.